- Home
- FMST vs NRSN Comparison
FMST vs NRSN Comparison
Compare FMST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- NRSN
- Stock Information
- Founded
- FMST 2005
- NRSN 2017
- Country
- FMST Canada
- NRSN Israel
- Employees
- FMST N/A
- NRSN N/A
- Industry
- FMST Other Metals and Minerals
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- NRSN Health Care
- Exchange
- FMST Nasdaq
- NRSN Nasdaq
- Market Cap
- FMST 28.2M
- NRSN 50.1M
- IPO Year
- FMST N/A
- NRSN 2021
- Fundamental
- Price
- FMST $2.29
- NRSN $1.79
- Analyst Decision
- FMST
- NRSN Buy
- Analyst Count
- FMST 0
- NRSN 2
- Target Price
- FMST N/A
- NRSN $14.00
- AVG Volume (30 Days)
- FMST 418.0K
- NRSN 218.4K
- Earning Date
- FMST 01-01-0001
- NRSN 08-05-2025
- Dividend Yield
- FMST N/A
- NRSN N/A
- EPS Growth
- FMST N/A
- NRSN N/A
- EPS
- FMST N/A
- NRSN N/A
- Revenue
- FMST N/A
- NRSN N/A
- Revenue This Year
- FMST N/A
- NRSN N/A
- Revenue Next Year
- FMST N/A
- NRSN N/A
- P/E Ratio
- FMST N/A
- NRSN N/A
- Revenue Growth
- FMST N/A
- NRSN N/A
- 52 Week Low
- FMST $0.55
- NRSN $0.60
- 52 Week High
- FMST $5.74
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- FMST 44.91
- NRSN 42.04
- Support Level
- FMST $2.18
- NRSN $1.83
- Resistance Level
- FMST $2.52
- NRSN $2.10
- Average True Range (ATR)
- FMST 0.25
- NRSN 0.14
- MACD
- FMST -0.02
- NRSN -0.02
- Stochastic Oscillator
- FMST 40.00
- NRSN 7.25
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.